ArticleDrug metabolism and disposition: the biological fate of chemicals2023
Biotransformation of the Novel Myeloperoxidase Inhibitor AZD4831 in Preclinical Species and Humans.
Open access · hybridAbstract read
In one paragraph
Article in Drug metabolism and disposition: the biological fate of chemicals, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 8 citations in OpenAlex.
- The effect of severe renal impairment on the pharmacokinetics, safety and tolerability of mitiperstat.British journal of clinical pharmacology · 2024Trial
- Pharmacokinetics and Tolerability of the Novel Myeloperoxidase Inhibitor Mitiperstat in Healthy Japanese and Chinese Volunteers.Clinical drug investigation · 2024Trial
- Stereoselective Biotransformation: Transfer of Learning to Advance Drug Metabolism and Biocatalysis.Angewandte Chemie (International ed. in English) · 2026Review
- Population Pharmacokinetics of the Novel Myeloperoxidase Inhibitor Mitiperstat.Pharmacology research & perspectives · 2026Article
- Review
- Myeloperoxidase as a Promising Therapeutic Target after Myocardial Infarction.Antioxidants (Basel, Switzerland) · 2024Review
- The Roles of Neutrophil-Derived Myeloperoxidase (MPO) in Diseases: The New Progress.Antioxidants (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 2 countries.
Ulrik JurvaDrug Metabolism and Pharmacokinetics, Research and Early Development, Cardiovascular, Renal and Metabolism (U.J., L.W., A-S.S., A.E., X.L., V.S.G.); Drug Metabolism and Pharmacokinetics, Research and Early Development, Respiratory and Immunology (C.L.), Medicinal Chemistry, Research and Early Development, Cardiovascular, Renal and Metabolism (T.A., J.S., K.W., T.I.), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; and Formerly of AstraZeneca (L.W., C.A.) ulrik.jurva@astrazeneca.com.
Lars WeidolfDrug Metabolism and Pharmacokinetics, Research and Early Development, Cardiovascular, Renal and Metabolism (U.J., L.W., A-S.S., A.E., X.L., V.S.G.); Drug Metabolism and Pharmacokinetics, Research and Early Development, Respiratory and Immunology (C.L.), Medicinal Chemistry, Research and Early Development, Cardiovascular, Renal and Metabolism (T.A., J.S., K.W., T.I.), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; and Formerly of AstraZeneca (L.W., C.A.).
Ann-Sofie SandingeDrug Metabolism and Pharmacokinetics, Research and Early Development, Cardiovascular, Renal and Metabolism (U.J., L.W., A-S.S., A.E., X.L., V.S.G.); Drug Metabolism and Pharmacokinetics, Research and Early Development, Respiratory and Immunology (C.L.), Medicinal Chemistry, Research and Early Development, Cardiovascular, Renal and Metabolism (T.A., J.S., K.W., T.I.), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; and Formerly of AstraZeneca (L.W., C.A.).
Carina LeanderssonDrug Metabolism and Pharmacokinetics, Research and Early Development, Cardiovascular, Renal and Metabolism (U.J., L.W., A-S.S., A.E., X.L., V.S.G.); Drug Metabolism and Pharmacokinetics, Research and Early Development, Respiratory and Immunology (C.L.), Medicinal Chemistry, Research and Early Development, Cardiovascular, Renal and Metabolism (T.A., J.S., K.W., T.I.), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; and Formerly of AstraZeneca (L.W., C.A.).
Anja EkdahlDrug Metabolism and Pharmacokinetics, Research and Early Development, Cardiovascular, Renal and Metabolism (U.J., L.W., A-S.S., A.E., X.L., V.S.G.); Drug Metabolism and Pharmacokinetics, Research and Early Development, Respiratory and Immunology (C.L.), Medicinal Chemistry, Research and Early Development, Cardiovascular, Renal and Metabolism (T.A., J.S., K.W., T.I.), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; and Formerly of AstraZeneca (L.W., C.A.).
Xue-Qing LiDrug Metabolism and Pharmacokinetics, Research and Early Development, Cardiovascular, Renal and Metabolism (U.J., L.W., A-S.S., A.E., X.L., V.S.G.); Drug Metabolism and Pharmacokinetics, Research and Early Development, Respiratory and Immunology (C.L.), Medicinal Chemistry, Research and Early Development, Cardiovascular, Renal and Metabolism (T.A., J.S., K.W., T.I.), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; and Formerly of AstraZeneca (L.W., C.A.).
Thomas AntonssonDrug Metabolism and Pharmacokinetics, Research and Early Development, Cardiovascular, Renal and Metabolism (U.J., L.W., A-S.S., A.E., X.L., V.S.G.); Drug Metabolism and Pharmacokinetics, Research and Early Development, Respiratory and Immunology (C.L.), Medicinal Chemistry, Research and Early Development, Cardiovascular, Renal and Metabolism (T.A., J.S., K.W., T.I.), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; and Formerly of AstraZeneca (L.W., C.A.).
Johan SundellDrug Metabolism and Pharmacokinetics, Research and Early Development, Cardiovascular, Renal and Metabolism (U.J., L.W., A-S.S., A.E., X.L., V.S.G.); Drug Metabolism and Pharmacokinetics, Research and Early Development, Respiratory and Immunology (C.L.), Medicinal Chemistry, Research and Early Development, Cardiovascular, Renal and Metabolism (T.A., J.S., K.W., T.I.), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; and Formerly of AstraZeneca (L.W., C.A.).
Kristina WesterlundDrug Metabolism and Pharmacokinetics, Research and Early Development, Cardiovascular, Renal and Metabolism (U.J., L.W., A-S.S., A.E., X.L., V.S.G.); Drug Metabolism and Pharmacokinetics, Research and Early Development, Respiratory and Immunology (C.L.), Medicinal Chemistry, Research and Early Development, Cardiovascular, Renal and Metabolism (T.A., J.S., K.W., T.I.), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; and Formerly of AstraZeneca (L.W., C.A.).
Carl AmilonDrug Metabolism and Pharmacokinetics, Research and Early Development, Cardiovascular, Renal and Metabolism (U.J., L.W., A-S.S., A.E., X.L., V.S.G.); Drug Metabolism and Pharmacokinetics, Research and Early Development, Respiratory and Immunology (C.L.), Medicinal Chemistry, Research and Early Development, Cardiovascular, Renal and Metabolism (T.A., J.S., K.W., T.I.), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; and Formerly of AstraZeneca (L.W., C.A.).
Tord InghardtDrug Metabolism and Pharmacokinetics, Research and Early Development, Cardiovascular, Renal and Metabolism (U.J., L.W., A-S.S., A.E., X.L., V.S.G.); Drug Metabolism and Pharmacokinetics, Research and Early Development, Respiratory and Immunology (C.L.), Medicinal Chemistry, Research and Early Development, Cardiovascular, Renal and Metabolism (T.A., J.S., K.W., T.I.), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; and Formerly of AstraZeneca (L.W., C.A.).
V Sashi GopaulDrug Metabolism and Pharmacokinetics, Research and Early Development, Cardiovascular, Renal and Metabolism (U.J., L.W., A-S.S., A.E., X.L., V.S.G.); Drug Metabolism and Pharmacokinetics, Research and Early Development, Respiratory and Immunology (C.L.), Medicinal Chemistry, Research and Early Development, Cardiovascular, Renal and Metabolism (T.A., J.S., K.W., T.I.), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; and Formerly of AstraZeneca (L.W., C.A.).
AstraZeneca (Finland) · FIAstraZeneca (Sweden) · SE
Funding
PHARMACOLOGY TRAINING GRANTT32GM008763 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI FREEL MEYERS, CAREN L. · 2000 to 2019
$6.1MNIGMS NIH HHS T32 GM008763
Abstract
We report herein an in-depth analysis of the metabolism of the novel myeloperoxidase inhibitor AZD4831 ((
Indexed as
GlucuronidesPeroxidaseAminesAnimalsBiotransformationChromatography, High Pressure LiquidDogsHumansMicePyrimidinesPyrrolesRatsAminesAZD4831GlucuronidesPeroxidasePyrimidinesPyrroles
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.